[Federal Register Volume 68, Number 237 (Wednesday, December 10, 2003)]
[Notices]
[Pages 68926-68931]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 03-30583]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Studies To Determine the Prevalence of a History of Traumatic 
Brain Injury (TBI) in an Institutionalized Population

    Announcement Type: New.
    Funding Opportunity Number: 04062.
    Catalog of Federal Domestic Assistance Number: 93.136.
    Key Dates:
    Letter of Intent Deadline: January 9, 2004.
    Application Deadline: February 18, 2003.

I. Funding Opportunity Description

    Authority: This program is authorized under sections 391(a) and 
301(a) of the Public Health Service Act (PHS Act) and 42 U.S.C. 241(a) 
and 280b(a) as amended.
    Purpose: The purpose of the program is to fund a cooperative 
agreement to conduct pilot studies to investigate methods for 
determining the prevalence of a history of traumatic brain injury (TBI) 
in an institutionalized population. For purposes of this RFA, 
``institutionalized'' refers to persons who are either incarcerated or 
residing in a nursing home. Research on only one of these populations 
should be proposed.
    Anecdotal reports suggest that a very large proportion of the 
prison population may have experienced one or more TBIs, with many of 
them occurring prior to incarceration. The cognitive deficits that can 
result from traumatic brain injuries often are not visible, and 
behavioral and emotional problems associated with TBI may be

[[Page 68927]]

attributed to other causes. Thus, prisoners with TBI as well as prison 
officials may not be aware of the signs, symptoms, and long term 
problems resulting from TBI, and therefore may not seek or provide 
appropriate treatment or other interventions. Better methods for 
identifying incarcerated persons with a history of TBI and related 
problems could lead to improved management of TBI in this population.
    An estimated 20 to 30 percent of persons hospitalized with moderate 
to severe TBI are discharged to nursing homes, including those for 
long-term care. Not all of the persons with TBI who are discharged to 
nursing homes are elderly, but little is known about the age 
distribution and other characteristics of this population. Of note, 
research on a small number of persons with TBI residing in long-term 
nursing facilities found that, with the proper rehabilitation, they 
recovered sufficient function to return home or live in a supported 
community living environment. Better information on the number and 
characteristics of persons with TBI living in nursing homes, including 
their functional levels, would inform the development of policies to 
ensure that they receive appropriate rehabilitation services that can 
help them return to the community.
    This program addresses the ``Healthy People 2010'' focus area of 
Injury and Violence Prevention.
    Measurable outcomes of the program will be in alignment with the 
following performance goal for the National Center for Injury 
Prevention and Control (NCIPC):
    [sbull] Conduct a targeted program of research to reduce injury-
related death and disability.

Research Objectives

    For research to identify TBI among prisoners:
    [sbull] To develop valid and reliable measure(s) for ascertaining 
the history of previous traumatic brain injuries (including those 
occurring prior to or during incarceration) within a subgroup of the 
incarcerated population (e.g., adult women or men in prison, or youth 
in the juvenile justice system), or to validate an existing instrument 
for use with this population.
    [sbull] To use these measure(s) to determine the prevalence of a 
history of TBI in an incarcerated population.
    For research to identify persons with TBI in nursing homes:
    [sbull] To determine the prevalence of persons admitted to nursing 
homes with a diagnosis of TBI, including those for long-term care, 
within a state, or alternatively a defined catchment area, for example, 
multiple census tracts, multiple counties, or a metropolitan area.
    [sbull] To determine the functional status and other 
characteristics of a sample of persons with TBI in long-term care 
facilities.

Activities

    Awardee activities for this program are as follows:
    [sbull] With assistance from the CDC, prepare a detailed research 
protocol for Institutional Review Board (IRB) approval by all 
cooperating institutions participating in the study, including CDC. The 
protocol shall include but is not limited to the following: A detailed 
description of a reliable and valid existing instrument(s) for use with 
the proposed population, or the methods for developing such 
instrument(s); recruitment and enrollment methods including the 
informed consent process and consent forms; methods for data handling 
and storage including methods for ensuring participant confidentiality; 
data analysis methods; and plans for data dissemination. Specific 
issues and approaches to conducting research in the proposed 
institutional setting, including any prior experience, must be 
described.
    [sbull] Develop a detailed operations manual documenting study 
methods.
    [sbull] Train study personnel.
    [sbull] Recruit study participants.
    [sbull] Collect and enter the data.
    [sbull] Provide case level data, without personal identifiers, to 
the CDC for use in collaborative analyses.
    [sbull] Analyze and interpret the data.
    [sbull] Report study findings, including those in peer-reviewed 
publications.
    In a cooperative agreement, CDC staff is substantially involved in 
the program activities, above and beyond routine grant monitoring.
    CDC Activities for this program are as follows:
    [sbull] Provide technical assistance where applicable and as 
necessary for effective study planning and management.
    [sbull] Assist in the development of a research protocol for 
Institutional (IRB) review by all cooperating institutions 
participating in the research. CDC will provide guidance about protocol 
format and content as well as scientific and human subjects 
considerations.
    [sbull] The CDC IRB will review and approve the protocol initially 
and on at least an annual basis until the research project is 
completed.
    [sbull] CDC staff will collaborate in the analysis of data and 
reporting of findings by participating as co-authors in the preparation 
of peer-reviewed publications.
    [sbull] CDC staff will convene routine conference calls with the 
recipient and conduct a site visit annually or as needed to review 
progress.

II. Award Information

    Type of Award: Cooperative agreement. CDC involvement in this 
program is listed in the Activities Section above.
    Fiscal Year Funds: 2004.
    Approximate Total Funding: $ 300,000.
    Approximate Number of Awards: Two.
    Approximate Average Award: $ 150,000.
    Floor of Award Range: $ 100,000.
    Ceiling of Award Range: $200,000.
    Anticipated Award Date: September 1, 2004.
    Budget Period Length: 12 months.
    Project Period Length: One year.
    Throughout the project period, CDC's commitment to continuation of 
awards will be conditioned on the availability of funds, evidence of 
satisfactory progress by the recipient (as documented in required 
reports), and the determination that continued funding is in the best 
interest of the Federal government.

III. Eligibility Information

1. Eligible Applicants

    Applications may be submitted by public and private nonprofit and 
for profit organizations and by governments and their agencies, such 
as:
    [sbull] Public nonprofit organizations
    [sbull] Private nonprofit organizations
    [sbull] For profit organizations
    [sbull] Small, minority, women-owned businesses
    [sbull] Universities
    [sbull] Colleges
    [sbull] Research institutions
    [sbull] Hospitals
    [sbull] Community-based organizations
    [sbull] Faith-based organizations
    [sbull] Federally recognized Indian tribal governments
    [sbull] Indian tribes
    [sbull] Indian tribal organizations
    [sbull] State and local governments or their bona fide agents (this 
includes the District of Columbia, the Commonwealth of Puerto Rico, the 
Virgin Islands, the Commonwealth of the Northern Marianna Islands, 
American Samoa, Guam, the Federated States of Micronesia, the Republic 
of the Marshall Islands, and the Republic of Palau)
    [sbull] Political subdivisions of States (in consultation with 
States)
    A bona fide agent is an agency/organization identified by the State 
as

[[Page 68928]]

eligible to submit an application under the State eligibility in lieu 
of a state application. If you are applying as a bona fide agent of a 
State or local government, you must provide a letter from the State or 
local government as documentation of your status. Place this 
documentation behind the first page of your application form.

2. Cost Sharing or Matching

    Matching funds are not required for this program.

3. Other Eligibility Requirements

    If your application is incomplete or non-responsive to the 
requirements listed below, it will not be entered into the review 
process. You will be notified that your application did not meet 
submission requirements.
    [sbull] Is there an appropriate degree of commitment and 
cooperation from other participating parties as evidenced by letters of 
support detailing the nature and extent of involvement? Letter(s) of 
support from appropriate officials from departments of corrections, 
nursing homes, or other agencies responsible for approving the use of 
existing data sets containing information on these populations, 
indicating approval for the research, must be included with the 
application.
    [sbull] Does the applicant describe research methods that are 
feasible and appropriate for the corrections setting?
    [sbull] Is there evidence of the experience and capacity for all 
key staff members including Curriculum Vitae (CV) and position 
descriptions?
    [sbull] Does the research team include expert(s) with experience 
conducting TBI research relevant to the proposed study?
    [sbull] Are the investigators requesting a funding amount that is 
greater than the upper ceiling of the award range?
    [sbull] Principal investigators (PI's) are encouraged to submit 
only one proposal in response to this program announcement. With few 
exceptions (e.g., research issues needing immediate public health 
attention), only one application per PI will be funded under this 
announcement.

    Note: Title 2 of the United States Code section 1611 states that 
an organization described in section 501(c)(4) of the Internal 
Revenue Code that engages in lobbying activities is not eligible to 
receive Federal funds constituting an award, grant, or loan.

4. Individuals Eligible To Become Principal Investigators

    Any individual with the skills, knowledge, and resources necessary 
to carry out the proposed research is invited to work with their 
institution to develop an application for support. Individuals from 
underrepresented racial and ethnic groups as well as individuals with 
disabilities are always encouraged to apply for CDC programs.

IV. Application and Submission Information

1. Address To Request Application Package

    To apply for this funding opportunity, use application form PHS 398 
(OMB number 0925-0001 rev. 5/2001). Forms and instructions are 
available in an interactive format on the CDC Web site, at the 
following Internet address: http://www.cdc.gov/od/pgo/forminfo.htm.
    Forms and instructions are also available in an interactive format 
on the National Institutes of Health (NIH) Web site at the following 
Internet address: http://grants.nih.gov/grants/funding/phs398/phs398.html.
    If you do not have access to the Internet, or if you have 
difficulty accessing the forms on-line, you may contact the CDC 
Procurement and Grants Office Technical Information Management Section 
(PGO-TIM) staff at: 770-488-2700. Application forms can be mailed to 
you.

2. Content and Form of Application Submission

Letter of Intent (LOI)
    CDC requests that you send a LOI if you intend to apply for this 
program. Although the LOI is not required, not binding, and does not 
enter into the review of your subsequent application, your LOI will be 
used to gauge the level of interest in this program, and to allow CDC 
to plan the application review. Your LOI must be written in the 
following format:
    [sbull] Maximum number of pages: Two;
    [sbull] Font size: 12-point unreduced;
    [sbull] Paper size: 8.5 by 11 inches;
    [sbull] Page margin size: One inch;
    [sbull] Single spaced;
    [sbull] Printed only on one side of page;
    [sbull] Written in English, no jargon.
    Your LOI must contain the following information:
    [sbull] Descriptive title of the proposed research;
    [sbull] Name, address, e-mail, and telephone number of the 
Principal Investigator;
    [sbull] Names of other key personnel;
    [sbull] Participating institutions;
    [sbull] Number and title of this Program Announcement (PA).
Application
    Follow the PHS 398 application instructions for content and 
formatting of your application. For further assistance with the PHS 398 
application form, contact GrantsInfo, telephone (301) 435-0714, email: 
[email protected].
    Your research plan should address activities to be conducted over 
the entire project period.
    You are required to have a Dun and Bradstreet Data Universal 
Numbering System (DUNS) number to apply for a grant or cooperative 
agreement from the Federal government. Your DUNS number must be entered 
in item 11 of the face page of the PHS 398 application form. The DUNS 
number is a nine-digit identification number, which uniquely identifies 
business entities. Obtaining a DUNS number is easy and there is no 
charge. To obtain a DUNS number, access http://www.dunandbradstreet.com 
or call 1-866-705-5711. For more information, see the CDC Web site at: 
http://www.cdc.gov/od/pgo/funding/pubcommt.htm.

3. Submission Dates and Times

    LOI Deadline Date: January 9, 2004.
    Application Deadline Date: February 18, 2004.
    Explanation of Deadlines: Applications must be received in the CDC 
Procurement and Grants Office by 4 p.m. eastern time on the deadline 
date. If you send your application by the United States Postal Service 
or commercial delivery service, you must ensure that the carrier will 
be able to guarantee delivery of the application by the closing date 
and time. If CDC receives your application after closing due to: (1) 
Carrier error, when the carrier accepted the package with a guarantee 
for delivery by the closing date and time, or (2) significant weather 
delays or natural disasters, you will be given the opportunity to 
submit documentation of the carriers guarantee. If the documentation 
verifies a carrier problem, CDC will consider the application as having 
been received by the deadline.
    This announcement is the definitive guide on application submission 
address and deadline. It supersedes information provided in the 
application instructions. If your application does not meet the 
deadline above, it will not be eligible for review, and will be 
discarded. You will be notified that you did not meet the submission 
requirements.
    CDC will not notify you upon receipt of your application. If you 
have a question about the receipt of your application, first contact 
your courier. If you still have a question, contact the PGO-TIM staff 
at: 770-488-2700. Before

[[Page 68929]]

calling, please wait two to three days after the application deadline. 
This will allow time for applications to be processed and logged.

4. Intergovernmental Review of Applications

    Executive Order 12372 does not apply to this program.

5. Funding Restrictions

    Restrictions, which must be taken into account while writing your 
budget, are as follows: none.
    If you are requesting indirect costs in your budget, you must 
include a copy of your indirect cost rate agreement. If your indirect 
cost rate is a provisional rate, the agreement must be less than 12 
months of age.

6. Other Submission Requirements

    LOI Submission Address: Submit your LOI by express mail, delivery 
service, fax, or e-mail to: Robin Forbes, Centers for Disease Control 
and Prevention, National Center for Injury Prevention and Control, 4770 
Buford Hwy, NE., Mailstop K-62, Atlanta, GA 30341. Telephone: 770-488-
4037; fax: 770-488-1662; email: [email protected].
    Application Submission Address: Submit the original and five copies 
of your application by mail or express delivery service to: Technical 
Information Management--PA 04062, CDC Procurement and Grants 
Office, 2920 Brandywine Road, Atlanta, GA 30341.
    Applications may not be submitted electronically at this time.

V. Application Review Information

1. Criteria

    You are required to provide measures of effectiveness that will 
demonstrate the accomplishment of the various identified objectives of 
the cooperative agreement. Measures of effectiveness must relate to the 
performance goals stated in the ``Purpose'' section of this 
announcement. Measures must be objective and quantitative, and must 
measure the intended outcome. These measures of effectiveness must be 
submitted with the application and will be an element of evaluation.
    The goals of CDC-supported research are to advance the 
understanding of biological systems, improve the control and prevention 
of disease, and enhance health. In the written comments, reviewers will 
be asked to evaluate the application in order to judge the likelihood 
that the proposed research will have a substantial impact on the 
pursuit of these goals.
    The scientific review group will address and consider each of the 
following criteria in assigning the application's overall score, 
weighting them as appropriate for each application.
    The application does not need to be strong in all categories to be 
judged likely to have major scientific impact and thus deserve a high 
priority score. For example, an investigator may propose to carry out 
important work that by its nature is not innovative, but is essential 
to move a field forward.
    The criteria are as follows:
    Significance: Does this study address an important problem? If the 
aims of the application are achieved, how will scientific knowledge be 
advanced? What will be the effect of these studies on the concepts or 
methods that drive this field?
    Approach: Are the conceptual framework, design, methods, and 
analyses adequately developed, well-integrated, and appropriate to the 
aims of the project? Does the applicant acknowledge potential problem 
areas and consider alternative tactics?
    Innovation: Does the project employ novel concepts, approaches or 
methods? Are the aims original and innovative? Does the project 
challenge existing paradigms or develop new methodologies or 
technologies?
    Investigator: Is the investigator appropriately trained and well 
suited to carry out this work? Is the work proposed appropriate to the 
experience level of the principal investigator and other researchers 
(if any)?
    Environment: Does the scientific environment in which the work will 
be done contribute to the probability of success? Does the proposed 
experiment take advantage of unique features of the scientific 
environment or employ useful collaborative arrangements? Is there 
evidence of institutional support?
    Additional Review Criteria: In addition to the above criteria, the 
following items will be considered in the determination of scientific 
merit and priority score:
    [sbull] Does the applicant describe either (a) existing instruments 
appropriate for use with the proposed population or (b) scientifically 
sound plans for developing such instrument(s)?
    [sbull] Does the applicant describe research methods appropriate 
for a study in the proposed institutional setting?
    [sbull] Are there adequate plans for data collection and data 
management including security of data and assurance of participant 
confidentiality?
    [sbull] Is there a statistical analysis plan appropriate for the 
study design?
    [sbull] Does the applicant provide a detailed and appropriate 
timeline for the study?
    Protection of Human Subjects from Research Risks: Does the 
application adequately address the requirements of Title 45 CFR Part 46 
for the protection of human subjects? Not scored; however, an 
application can be disapproved if the research risks are sufficiently 
serious and protection against risks is so inadequate as to make the 
entire application unacceptable.
    Inclusion of Women and Minorities in Research: Does the application 
adequately address the CDC Policy requirements regarding the inclusion 
of woman, ethnic, and racial groups in the proposed research? This 
includes: (1) The proposed plan for the inclusion of both sexes and 
racial and ethnic minority populations for appropriate representation; 
(2) the proposed justification when representation is limited or 
absent; (3) a statement as to whether the design of the study is 
adequate to measure differences when warranted; and (4) a statement as 
to whether the plans for recruitment and outreach for study 
participants include the process of establishing partnerships with 
community(ies) and recognition of mutual benefits.
Inclusion of Children as Participants in Research Involving Human 
Subjects
    The NIH maintains a policy that children (i.e., individuals under 
the age of 21) must be included in all human subjects research, 
conducted or supported by the NIH, unless there are scientific and 
ethical reasons not to include them. This policy applies to all initial 
(Type 1) applications submitted for receipt dates after October 1, 
1998.
    All investigators proposing research involving human subjects 
should read the ``NIH Policy and Guidelines'' on the inclusion of 
children as participants in research involving human subjects that is 
available at: http://grants.nih.gov/grants/funding/children/children.htm.
    Budget: The reasonableness of the proposed budget and the requested 
period of support in relation to the proposed research. This 
announcement does not use the modular budget format.

2. Review and Selection Process

    Applications will be reviewed for completeness by the Procurement 
and Grants Office (PGO) and for responsiveness for other eligibility 
requirements by the National Center for Injury Prevention and Control. 
Incomplete applications and applications that are non-responsive will 
not advance through the review

[[Page 68930]]

process. You will be notified that you did not meet submission 
requirements.
    Applications that are complete and responsive to the PA will be 
evaluated for scientific and technical merit by an appropriate peer 
review group convened by the NCIPC in accordance with the review 
criteria listed above. As part of the initial merit review, all 
applications will:
    [sbull] Undergo a process in which only those applications deemed 
to have the highest scientific merit, generally the top half of the 
applications under review, will be discussed and assigned a priority 
score.
    [sbull] Receive a written critique.
    [sbull] Receive a second level review by the Science and Program 
Review Subcommittee (SPRS) of the Advisory Committee for Injury 
Prevention and Control (ACIPC).
    Applications that are complete and responsive to the PA will be 
subjected to a preliminary evaluation (streamline review) by a peer 
review committee, the Initial Review Group (IRG) convened by NCIPC, to 
determine if the application is of sufficient technical and scientific 
merit to warrant further review by the IRG. CDC will withdraw from 
further consideration applications judged to be noncompetitive and 
promptly notify the principal investigator or program director and the 
official signing for the applicant organization. Those applications 
judged to be competitive will be further evaluated by a dual review 
process.
    1. The primary review will be a peer review conducted by the IRG. 
All applications will be reviewed for scientific merit in accordance 
with the review criteria listed above. Applications will be assigned a 
priority score based on the National Institutes of Health (NIH) scoring 
system of 100-500 points.
    2. The secondary review will be conducted by the Science and 
Program Review Subcommittee (SPRS) of NCIPC's Advisory Committee for 
Injury Prevention and Control (ACIPC). The ACIPC Federal agency experts 
will be invited to attend the secondary review, and will receive 
modified briefing books (i.e., abstracts, strengths and weaknesses from 
summary statements, and project officer's briefing materials). ACIPC 
Federal agency experts will be encouraged to participate in 
deliberations when applications address overlapping areas of research 
interest, so that unwarranted duplication in federally-funded research 
can be avoided and special subject area expertise can be shared. The 
NCIPC Division Associate Directors for Science (ADS) or their designees 
will attend the secondary review in a similar capacity as the ACIPC 
Federal agency experts to assure that research priorities of the 
announcement are understood and to provide background regarding current 
research activities. Only SPRS members will vote on funding 
recommendations, and their recommendations will be carried to the 
entire ACIPC for voting by the ACIPC members in closed session. If any 
further review is needed by the ACIPC, regarding the recommendations of 
the SPRS, the factors considered will be the same as those considered 
by the SPRS.
    The committee's responsibility is to develop funding 
recommendations for the NCIPC Director based on the results of the 
primary review, the relevance and balance of proposed research relative 
to the NCIPC programs and priorities, and to assure that unwarranted 
duplication of federally-funded research does not occur. The secondary 
review committee has the latitude to recommend to the NCIPC Director, 
to reach over better-ranked proposals in order to assure maximal impact 
and balance of proposed research. The factors to be considered will 
include:
    a. The results of the primary review including the application's 
priority score as the primary factor in the selection process.
    b. The relevance and balance of proposed research relative to the 
NCIPC programs and priorities.
    c. The significance of the proposed activities in relation to the 
priorities and objectives stated in ``Healthy People 2010,'' the 
Institute of Medicine report, ``Reducing the Burden of Injury,'' and 
the ``CDC Injury Research Agenda.''
    Award Criteria: Criteria that will be used to make award decisions 
include:
    [sbull] Scientific merit (as determined by peer review)
    [sbull] Availability of funds
    [sbull] Programmatic priorities

VI. Award Administration Information

1. Award Notices

    Successful applicants will receive a Notice of Grant Award (NGA) 
from the CDC Procurement and Grants Office. The NGA shall be the only 
binding, authorizing document between the recipient and CDC. The NGA 
will be signed by an authorized Grants Management Officer, and mailed 
to the recipient fiscal officer identified in the application.

2. Administrative and National Policy Requirements

    45 CFR part 74 and 92.

    For more information on the Code of Federal Regulations, see the 
National Archives and Records Administration at the following Internet 
address: http://www.access.gpo.gov/nara/cfr/cfr-table-search.html.
    The following additional requirements apply to this project:

[sbull] AR-1--Human Subjects Requirements
[sbull] AR-2--Requirements for Inclusion of Women and Racial and Ethnic 
Minorities in Research
[sbull] AR-6--Patient Care
[sbull] AR-8--Public Health System Reporting Requirements
[sbull] AR-9--Paperwork Reduction Act Requirements
[sbull] AR-10--Smoke-Free Workplace Requirements
[sbull] AR-11--Healthy People 2010
[sbull] AR-12--Lobbying Restrictions
[sbull] AR-13--Prohibition on Use of CDC Funds for Certain Gun Control 
Activities
[sbull] AR-14--Accounting System Requirements
[sbull] AR-15--Proof of Non-Profit Status
[sbull] AR-21--Small, Minority, and Women-Owned Business
[sbull] AR-22--Research Integrity
[sbull] AR-23--States and Faith-Based Organizations
[sbull] AR-24--Health Insurance Portability and Accountability Act 
Requirements
[sbull] AR-25--Release and Sharing of Data

    Starting with the December 1, 2003, receipt date, all NCIPC 
funded investigators seeking more than $500,000 in total costs in a 
single year are expected to include a plan describing how the final 
research data will be shared/released or explain why data sharing is 
not possible. Details on data sharing/release, including the 
timeliness and name of the project data steward, should be included 
in a brief paragraph immediately following the Research Plan Section 
of the PHS 398 form. References to data sharing/release may also be 
appropriate in other sections of the application (e.g. background 
and significance, human subjects requirements, etc.) The content of 
the data sharing/release plan will vary, depending on the data being 
collected and how the investigator is planning to share the data. 
The data sharing/release plan will not count towards the application 
page limit and will not factor into the determination of scientific 
merit or priority scores. Investigators should seek guidance from 
their institutions on issues related to institutional policies, 
local IRB rules, as well as local, State and Federal laws and 
regulations, including the Privacy Rule.
    Further detail on the requirements for addressing data sharing 
in applications for NCIPC funding may be obtained by contacting 
NCIPC program staff or visiting the NCIPC Internet Web site: at 
http://www.cdc.gov/ncipc/osp/sharing_policy.htm.

    Additional information on these requirements can be found on the 
CDC Web site at the following Internet address: http://www.cdc.gov/od/pgo/funding/ARs.htm.

[[Page 68931]]

3. Reporting

    You must provide CDC with an original, plus two copies of the 
following reports:
    1. Interim progress report, (PHS 2590, OMB Number 0925-0001, rev. 
5/2001) no less than 90 days before the end of the budget period. The 
progress report will serve as your non-competing continuation 
application, and must contain the following elements:
    a. Current Budget Period Activities Objectives.
    b. Current Budget Period Financial Progress.
    c. New Budget Period Program Proposed Activity Objectives.
    d. Detailed Line-Item Budget and Justification.
    e. Additional Requested Information.
    2. Financial status report, no more than 90 days after the end of 
the budget period.
    3. Final financial and performance reports, no more than 90 days 
after the end of the project period.
    These reports must be sent to the Grants Management Specialist 
listed in the ``Agency Contacts'' section of the announcement.

VII. Agency Contacts

    For general questions about this announcement, contact: Technical 
Information Management Section, PA04062, CDC Procurement and 
Grants Office, 2920 Brandywine Road, Atlanta, GA 30341. Telephone: 770-
488-2700.
    For scientific/research program technical assistance, contact: 
William K. Ramsey, Project Officer, Division of Injury and Disability 
Outcomes and Programs, Centers for Disease Control and Prevention, 4770 
Buford Highway, Mail Stop F-41, Chamblee, GA 30341. Telephone: 770-488-
1226; e-mail: [email protected].
    For questions about peer review, contact: Gwendolyn Cattledge, 
Scientific Review Administrator, Centers for Disease Control and 
Prevention, National Center for Injury Prevention and Control, 4770 
Buford Highway, NE., MailStop K-02, Atlanta, GA 30341. Telephone: 770-
488-1430; e-mail: [email protected].
    For budget assistance, contact: Angie Nation, Grants Management 
Specialist, CDC Procurement and Grants Office, 2920 Brandywine Road, 
Atlanta, GA 30341. Telephone: 770-488-2719; e-mail: [email protected].

    Dated: December 4, 2003.
Edward Schultz,
Acting Director, Procurement and Grants Office, Centers for Disease 
Control and Prevention.
[FR Doc. 03-30583 Filed 12-9-03; 8:45 am]
BILLING CODE 4163-18-P